Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Carilex Medical's Enterprise Value is NT$596.6 Mil.
Carilex Medical's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-36.9 Mil. Therefore, Carilex Medical's EV-to-EBIT ratio for today is -16.18.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Carilex Medical's Enterprise Value is NT$596.6 Mil.
Carilex Medical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-5.4 Mil. Therefore, Carilex Medical's EV-to-EBITDA ratio for today is -109.91.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Carilex Medical's Enterprise Value is NT$596.6 Mil.
Carilex Medical's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$338.6 Mil. Therefore, Carilex Medical's EV-to-Revenue ratio for today is 1.76.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Carilex Medical's Enterprise Value is NT$596.6 Mil.
Carilex Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$36.0 Mil. Therefore, Carilex Medical's EV-to-FCF ratio for today is 16.55.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Carilex Medical (ROCO:7726) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Carilex Medical's current Enterprise Value is NT$596.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Carilex Medical's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-36.9 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Carilex Medical's current Enterprise Value is NT$596.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Carilex Medical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-5.4 Mil.
Carilex Medical's current Enterprise Value is NT$596.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Carilex Medical's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$338.6 Mil.
Carilex Medical's current Enterprise Value is NT$596.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Carilex Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was NT$46.6 Mil.
Carilex Medical's current Enterprise Value is NT$596.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Carilex Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$36.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carilex Medical Enterprise Value Related Terms
Carilex Medical Enterprise Value Historical Data
* Premium members only.
The historical data trend for Carilex Medical's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7726 vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, Carilex Medical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carilex Medical Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carilex Medical's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Carilex Medical's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Carilex Medical's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of NT$596.6 Mil mean?
Carilex Medical (ROCO:7726) has a Enterprise Value of NT$596.6 Mil as of Jul. 07, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Carilex Medical and its competitors.
Is Carilex Medical's Enterprise Value too high?
Carilex Medical's current Enterprise Value is NT$596.6 Mil. Overall, Carilex Medical has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Carilex Medical's Enterprise Value compare to ABT and SYK?
Carilex Medical's Enterprise Value of NT$596.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Carilex Medical and its competitors. Carilex Medical's current Enterprise Value is NT$596.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carilex Medical stock overvalued right now?
Carilex Medical (ROCO:7726) has a current Enterprise Value of NT$596.6 Mil. The current Enterprise Value is NT$596.6 Mil. Carilex Medical's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Carilex Medical (ROCO:7726), the current Enterprise Value is NT$596.6 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Carilex Medical Inc is a company engaged in the wound care industry by developing leading-edge technology in the prevention and treatment of wounds. Their expertise is in research and development, manufacturing, and quality control and assurance allow us to provide unparalleled products in wound care management in the form of comprehensive product lines proven to prevent and manage pressure sores and wounds. They offer products in the form of Support Surfaces, Chair Cushion and Negative Pressure Wound Therapy.
34GF Score
Get the complete analysis for ROCO:7726
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7726 has been successfully added to your 
